Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Astellas/FibroGen's anemia drug for CKD patients approved in Japan; Researchers propose combo to stay ahead of KRAS ...
6 years ago
News Briefing
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
6 years ago
Pharma
Intrexon unit pushes back against claims its GM mosquitoes are making disease-friendly mutants
6 years ago
R&D
FDA+
Chris Roberts jumps back into biotech with CSO gig at Black Diamond; Troubled Five Prime appoints interim CEO
6 years ago
Peer Review
Purdue threatens to walk away from settlement, asks to pay employees millions in bonuses
6 years ago
Pharma
Boehringer Ingelheim enlists another virtual biotech partner for its foray into retinal diseases
6 years ago
Deals
Genentech submits a big plan to expand its South San Francisco footprint
6 years ago
R&D
Pharma
As Nasdaq enrolls the final batch of 2019 IPOs, how have the numbers compared to past years?
6 years ago
Financing
Emmaus rescinds EU marketing application, following negative review
6 years ago
Pharma
FDA+
While Novartis banishes Zolgensma scandal scars — Biogen goes on a Spinraza 'offensive'
6 years ago
R&D
Pharma
Eyeing big therapeutic push, Ginkgo bags $290M to build a cell programming empire
6 years ago
Financing
Speaker Nancy Pelosi to unveil bill for federally negotiated drug prices
6 years ago
People
Pharma
Alzheimer’s research in line for $350M boost as Senate proposes $3B hike to NIH budget; Allogene teams up with ...
6 years ago
News Briefing
Cancer trials aimed at 'surrogate' targets miss bigger mark — study
6 years ago
R&D
Zolgensma didn't cause an infant death, AveXis execs say as they spotlight long-term data
6 years ago
R&D
Pharma
Jeff Kindler's Centrexion renews bid to make public debut
6 years ago
Financing
Startups
'A fourth revolution in cancer therapies': ARCH-backed Boundless Bio flashes big check, makes bigger promises in ...
6 years ago
Financing
Startups
Biotech boards burdened: Bridging the success gap
6 years ago
Financing
Startups
FDA lays out tech modernization action plan
6 years ago
FDA+
'Disconnect the bastards' — one biotech's plan to break cancer cells' unified defenses
6 years ago
R&D
Cell/Gene Tx
Senators to FTC: Don't let the big Celgene and Allergan buyouts hurt R&D and consumers
6 years ago
People
R&D
Young anti-aging field takes big step with Mayo Clinic senolytics showcase
6 years ago
R&D
vTv Therapeutics reports additional positive PhII data; Shanghai Henlius prices $410 million IPO at bottom of range
6 years ago
News Briefing
A favorite in Alexion’s C-suite is leaving, and some mighty surprised analysts aren’t the least bit happy about ...
6 years ago
People
First page
Previous page
911
912
913
914
915
916
917
Next page
Last page